kymera therapeutics gilead

News

Gilead, Kymera

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the deal,

Seeking Alpha on MSN · 2d

Gilead and Kymera in pact to develop cancer drugs

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to develop and sell a band of cancer drugs. Under the deal, Kymera could receive up to $750M,

Yahoo Finance · 6h

Kymera’s partnerships with Sanofi and Gilead drive value

Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Medical Dialogues1d

Gilead Sciences, Kymera Therapeutics ink pact to develop novel oral molecular glue CDK2 degraders

Gilead Sciences, Inc. and Kymera Therapeutics, Inc., have entered into an exclusive option and license agreement for ...

PharmExec2d

Gilead, Kymera Launch Collaboration on Novel Oral CDK2 Degraders for Solid Tumors

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Morningstar2d

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Morningstar

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results